A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 76 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-02.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 7 that started in 2010, is one of 5 in phase 2, and was the 8th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 40th largest by enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2010, is one of 34 in phase 2, and was the 48th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265
LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
Drug: LY2189265
Placebo: subcutaneous (SC), once weekly (QW)
Drug: Placebo
Administered as a subcutaneous injection once weekly for 26 weeks
Also known as: Dulaglutide
Administered as a subcutaneous injection once weekly for 26 weeks
Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 weeks
Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)
Mean 24-hour diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)
Mean 24-hour heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure
Mean 24-hour pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)
Mean 24-hour mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)
Mean daytime and nighttime systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic SBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)
Mean daytime and nighttime diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic DBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)
Daytime and nighttime heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic HR was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure
Mean daytime and nighttime pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)
Mean daytime and nighttime mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)
Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Percentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with Chi-squared test/Fisher's exact test.
Time frame: Baseline and 16 and 26 weeks
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Change From Baseline to 16 and 26 Weeks on Pancreatic Enzymes
Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks on Serum Calcitonin
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)
Time frame: Baseline, 16 weeks
Change From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Number of Events of Adjudicated Pancreatitis up to 26 Weeks
The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Number of Participants With Adjudicated Cardiovascular Events up to 26 Weeks
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Anti-LY2189265 Antibodies
LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 16 and 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (30 weeks). The number of participants with initial postbaseline detection of treatment-emergent (defined as a 4-fold increase in the ADA titer from baseline) anti-drug (LY2189265) ADA at each time point were summarized.
Time frame: Baseline, 16, 26, and 30 weeks
Rate of Hypoglycemic Episodes
Hypoglycemic events (HE) were classified as severe (defined as an HE requiring assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as an HE without typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), nocturnal (defined as any HE occurring between bedtime and waking with a measured blood glucose of ≤3.9 mmol/L), or non-nocturnal. Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Logit link. Negative binomial mean was adjusted by treatment, visit, and visit by treatment interaction. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline, 16 and 26 weeks
Change From Baseline to 16 and 26 Weeks in Body Weight
Least Squares (LS) means was calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
Time frame: Baseline, 16 and 26 weeks
Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration). Evaluable pharmacokinetic concentrations from the 4, 8, 12, 16, and 26 weeks timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
Time frame: 4, 8, 12, 16, and 26 weeks
| Milestone | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Started | 251 | 254 | 250 |
| Received at least one dose of study drug | 251 | 254 | 250 |
| Completed | 199 | 225 | 206 |
| Not completed | 52 | 29 | 44 |
| Withdrew: Adverse event | 22 | 6 | 11 |
| Withdrew: Withdrawal by subject | 20 | 12 | 13 |
| Withdrew: Sponsor decision | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 4 | 5 |
| Withdrew: Physician decision | 5 | 3 | 6 |
| Withdrew: Entry criteria not met | 1 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 2 | 6 |
Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) | -3.41 ± 0.61 | -1.70 ± 0.58 | -0.63 ± 0.59 |
Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) | -2.51 ± 0.63 | -1.56 ± 0.60 | 0.15 ± 0.62 |
Mean 24-hour diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg)] | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean 24-Hour, Week 16 | -0.23 ± 0.38 | -0.13 ± 0.37 | -0.55 ± 0.37 |
| Mean 24-Hour, Week 26 | 0.26 ± 0.40 | -0.09 ± 0.38 | -0.24 ± 0.39 |
Mean 24-hour heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| beats per minute (bpm) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean 24-Hour HR, Week 16 | 3.70 ± 0.45 | 2.48 ± 0.43 | 0.86 ± 0.44 |
| Mean 24-Hour HR, Week 26 | 4.18 ± 0.47 | 1.94 ± 0.46 | 0.68 ± 0.47 |
Mean 24-hour pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean 24-Hour PP, Week 16 | -3.07 ± 0.36 | -1.60 ± 0.35 | -0.02 ± 0.36 |
| Mean 24-Hour PP, Week 26 | -2.64 ± 0.38 | -1.53 ± 0.37 | 0.46 ± 0.37 |
Mean 24-hour mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 | -1.31 ± 0.43 | -0.65 ± 0.42 | -0.60 ± 0.42 |
| Week 26 | -0.74 ± 0.44 | -0.57 ± 0.42 | -0.15 ± 0.43 |
Mean daytime and nighttime systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic SBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean Daytime SBP, Week 16 (n=247, n=251, n=249) | -3.67 ± 0.66 | -1.57 ± 0.63 | -0.34 ± 0.64 |
| Mean Daytime SBP, Week 26 (n=247, n=251, n=249) | -2.52 ± 0.68 | -1.47 ± 0.65 | 0.35 ± 0.67 |
| Mean Nighttime SBP, Week 16 (n=247, n=251, n=249) | -2.32 ± 0.76 | -1.23 ± 0.73 | -1.08 ± 0.74 |
| Mean Nighttime SBP, Week 26 (n=247, n=251, n=249) | -2.40 ± 0.75 | -1.43 ± 0.72 | -0.05 ± 0.73 |
| Mean Clinic SBP, Week 16 (n=251, n=254, n=250) | -2.33 ± 0.75 | -1.26 ± 0.72 | -0.73 ± 0.73 |
| Mean Clinic SBP, Week 26 (n=251, n=254, n=250) | -2.29 ± 0.77 | -0.74 ± 0.74 | 0.40 ± 0.75 |
Mean daytime and nighttime diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic DBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean Daytime DBP, Week 16 (n=247, n=251, n=249) | -0.09 ± 0.43 | 0.14 ± 0.41 | -0.30 ± 0.42 |
| Mean Daytime DBP, Week 26 (n=247, n=251, n=249) | 0.52 ± 0.43 | 0.08 ± 0.41 | -0.07 ± 0.42 |
| Mean Nighttime DBP, Week 16 (n=247, n=251, n=249) | -0.01 ± 0.49 | -0.28 ± 0.48 | -1.10 ± 0.48 |
| Mean Nighttime DBP, Week 26 (n=247, n=251, n=249) | -0.22 ± 0.51 | -0.42 ± 0.50 | -0.69 ± 0.51 |
| Mean Clinic DBP, Week 16 (n=251, n=254, n=250) | -0.21 ± 0.52 | 0.76 ± 0.50 | -0.21 ± 0.51 |
| Mean Clinic DBP, Week 26 (n=251, n=254, n=250) | 0.59 ± 0.50 | 0.69 ± 0.48 | 0.61 ± 0.49 |
Daytime and nighttime heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic HR was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.
| beats per minute (bpm) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean Daytime HR, Week 16 (n=247, n=251, n=249) | 3.56 ± 0.50 | 2.22 ± 0.49 | 1.07 ± 0.49 |
| Mean Daytime HR, Week 26 (n=247, n=251, n=249) | 4.24 ± 0.51 | 1.59 ± 0.49 | 0.67 ± 0.50 |
| Mean Nighttime HR, Week 16 (n=247, n=251, n=249) | 4.60 ± 0.51 | 3.43 ± 0.49 | 0.65 ± 0.50 |
| Mean Nighttime HR, Week 26 (n=247, n=251, n=249) | 4.76 ± 0.57 | 3.01 ± 0.54 | 0.77 ± 0.55 |
| Mean Clinic HR, Week 16 (n=251, n=254, n=250) | 3.97 ± 0.49 | 2.11 ± 0.48 | 0.46 ± 0.48 |
| Mean Clinic HR, Week 26 (n=251, n=254, n=250) | 4.89 ± 0.54 | 1.93 ± 0.52 | -0.11 ± 0.53 |
Mean daytime and nighttime pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean Daytime PP, Week 16 | -3.46 ± 0.40 | -1.76 ± 0.38 | 0.01 ± 0.39 |
| Mean Daytime PP, Week 26 | -2.90 ± 0.42 | -1.62 ± 0.41 | 0.51 ± 0.42 |
| Mean Nighttime PP, Week 16 | -2.23 ± 0.45 | -0.92 ± 0.43 | 0.02 ± 0.44 |
| Mean Nighttime PP, Week 26 | -2.09 ± 0.43 | -0.96 ± 0.41 | 0.65 ± 0.42 |
Mean daytime and nighttime mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimeters of mercury (mmHg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Mean Daytime MAP, Week 16 | -1.30 ± 0.48 | -0.42 ± 0.46 | -0.33 ± 0.47 |
| Mean Daytime MAP, Week 26 | -0.51 ± 0.49 | -0.42 ± 0.47 | 0.05 ± 0.48 |
| Mean Nighttime MAP, Week 16 | -0.80 ± 0.56 | -0.59 ± 0.53 | -1.11 ± 0.54 |
| Mean Nighttime MAP, Week 26 | -0.96 ± 0.57 | -0.76 ± 0.54 | -0.50 ± 0.56 |
Glycosylated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| percentage of HbA1c | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 | -1.18 ± 0.06 | -1.04 ± 0.05 | -0.06 ± 0.05 |
| Week 26 | -1.01 ± 0.07 | -0.89 ± 0.06 | -0.02 ± 0.06 |
Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| millimoles per liter (mmol/L) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 | -2.05 ± 0.13 | -1.94 ± 0.13 | -0.30 ± 0.13 |
| Week 26 | -1.67 ± 0.15 | -1.66 ± 0.15 | 0.00 ± 0.15 |
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with Chi-squared test/Fisher's exact test.
| percentage of participants | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| HbA1c levels <7.0%, Baseline | 6.8 | 6.7 | 8.0 |
| HbA1c levels ≤6.5%, Baseline | 0.0 | 0.4 | 0.4 |
| HbA1c levels <7.0%, Week 16 (n=216, n=234, n=225) | 66.7 | 59.0 | 12.9 |
| HbA1c levels ≤6.5%, Week 16 (n=216, n=234, n=225) | 45.8 | 36.8 | 6.2 |
| HbA1c levels <7.0%, Week 26 (n=206, n=226, n=210) | 62.1 | 54.9 | 14.3 |
| HbA1c levels ≤6.5%, Week 26 (n=206, n=226, n=210) | 38.8 | 35.8 | 5.2 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events at 26 Weeks | 160 | 156 | 162 |
Amylase (total and pancreas-derived) and lipase concentrations were measured.
| units per liter | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Amylase, Total, Week 16 (n=214, 227, 224) | 6.00 (-2.00 to 13.00) | 5.00 (-3.00 to 14.00) | 0.00 (-6.00 to 7.00) |
| Amylase, Total, Week 26 (n=205, 220, 209) | 7.00 (-2.00 to 16.00) | 4.00 (-2.00 to 15.50) | 0.00 (-5.00 to 6.00) |
| Amylase, Pancreas-derived, Wk 16 (n=213, 227, 224) | 4.00 (0.00 to 9.00) | 3.00 (-1.00 to 9.00) | 1.00 (-3.50 to 4.00) |
| Amylase, Pancreas-derived, Wk 26 (n=204, 220, 209) | 5.00 (1.00 to 10.00) | 3.50 (0.00 to 9.50) | 1.00 (-3.00 to 4.00) |
| Lipase, Week 16 (n=214, 227, 224) | 4.00 (-2.00 to 14.00) | 3.00 (-4.00 to 12.00) | -1.00 (-7.00 to 6.00) |
| Lipase, Week 26 (n=205, 220, 209) | 6.00 (-1.00 to 14.00) | 5.00 (-3.00 to 13.00) | 0.00 (-6.00 to 5.00) |
| picograms per milliliter (pg/mL) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 (n=213, n=223, n=223) | -0.30 ± 1.87 | -0.03 ± 1.81 | -0.39 ± 1.24 |
| Week 26 (n=202, n=220, n=209) | -0.19 ± 1.73 | 0.02 ± 2.04 | -0.05 ± 2.38 |
| milligram per liter (mg/L) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP) | -0.79 ± 4.91 | -0.20 ± 7.96 | 0.29 ± 6.73 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| milliseconds (msec) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| QTcF Interval, Week 16 (n=248, n=250, n=246) | -2.31 ± 0.97 | -0.96 ± 0.91 | 1.06 ± 0.93 |
| QTcF Interval, Week 26 (n=248, n=250, n=246) | -1.73 ± 0.96 | -0.93 ± 0.92 | 1.26 ± 0.94 |
| PR Interval, Week 16 (n=248, n=250, n=244) | 4.96 ± 0.98 | 3.67 ± 0.92 | 0.01 ± 0.95 |
| PR Interval, Week 26 (n=248, n=250, n=244) | 3.32 ± 0.86 | 3.17 ± 0.81 | -1.98 ± 0.84 |
The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Number of Events of Adjudicated Pancreatitis up to 26 Weeks | 0 | 0 | 0 |
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Any cardiovascular event | 1 | 1 | 4 |
| Any fatal cardiovascular event | 0 | 0 | 0 |
| Any non-fatal cardiovascular event | 1 | 1 | 4 |
LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 16 and 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (30 weeks). The number of participants with initial postbaseline detection of treatment-emergent (defined as a 4-fold increase in the ADA titer from baseline) anti-drug (LY2189265) ADA at each time point were summarized.
| participants | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 | 2 | 0 | 0 |
| Week 26 | 1 | 3 | 0 |
| Week 30 | 0 | 1 | 0 |
Hypoglycemic events (HE) were classified as severe (defined as an HE requiring assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as an HE without typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), nocturnal (defined as any HE occurring between bedtime and waking with a measured blood glucose of ≤3.9 mmol/L), or non-nocturnal. Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Logit link. Negative binomial mean was adjusted by treatment, visit, and visit by treatment interaction. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per 30 days | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Severe | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Documented Symptomatic | 0.14 ± 0.43 | 0.16 ± 0.59 | 0.08 ± 0.39 |
| Asymptomatic | 0.17 ± 0.89 | 0.15 ± 0.59 | 0.06 ± 0.25 |
| Nocturnal | 0.06 ± 0.30 | 0.12 ± 0.64 | 0.03 ± 0.22 |
| Non-nocturnal | 0.29 ± 0.97 | 0.26 ± 0.70 | 0.15 ± 0.44 |
Least Squares (LS) means was calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.
| kilogram (kg) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Week 16 | -1.84 ± 0.18 | -0.83 ± 0.18 | -0.13 ± 0.18 |
| Week 26 | -1.85 ± 0.23 | -0.86 ± 0.22 | -0.08 ± 0.22 |
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration). Evaluable pharmacokinetic concentrations from the 4, 8, 12, 16, and 26 weeks timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
| nanograms*hour per liter (ng*h/L) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 |
|---|---|---|
| Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC) | 11208 ± 3744 | 5998 ± 2003 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 Milligram (mg) LY2189265 | — | 12/251 (4.8%) | 164/251 (65.3%) |
| 0.75 Milligram (mg) LY2189265 | — | 8/254 (3.1%) | 161/254 (63.4%) |
| Placebo | — | 8/250 (3.2%) | 163/250 (65.2%) |
| Event | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| Uterine dilation and curettageSurgical and medical procedures | 0/121 | 0/123 | 1/119 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/121 | 0/123 | 0/119 |
| CholelithiasisHepatobiliary disorders | 2/251 | 0/254 | 0/250 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/130 | 0/131 | 1/131 |
| Coronary artery diseaseCardiac disorders | 0/251 | 0/254 | 1/250 |
| Ventricular tachycardiaCardiac disorders | 0/251 | 0/254 | 1/250 |
| GranulomaGeneral disorders | 0/251 | 0/254 | 1/250 |
| DiverticulitisInfections and infestations | 0/251 | 0/254 | 1/250 |
| Septic shockInfections and infestations | 0/251 | 0/254 | 1/250 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/251 | 0/254 | 1/250 |
| Event | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 35/251 | 18/254 | 16/250 |
| DiarrhoeaGastrointestinal disorders | 31/251 | 24/254 | 20/250 |
| HeadacheNervous system disorders | 25/251 | 21/254 | 25/250 |
| NasopharyngitisInfections and infestations | 23/251 | 19/254 | 24/250 |
| VomitingGastrointestinal disorders | 19/251 | 11/254 | 11/250 |
| Decreased appetiteMetabolism and nutrition disorders | 17/251 | 9/254 | 3/250 |
| DyspepsiaGastrointestinal disorders | 11/251 | 15/254 | 6/250 |
| Back painMusculoskeletal and connective tissue disorders | 9/251 | 12/254 | 13/250 |
| DizzinessNervous system disorders | 13/251 | 10/254 | 7/250 |
| Upper respiratory tract infectionInfections and infestations | 7/251 | 8/254 | 12/250 |
Participants who received at least one dose of LY2189265 or Placebo.
| Age, Continuous(years) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.96 ± 10.14 | 57.05 ± 10.17 | 56.43 ± 10.50 | 56.48 ± 10.27 |
| Sex: Female, Male(Participants) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Female | 121 | 123 | 119 | 363 |
| Male | 130 | 131 | 131 | 392 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 95 | 101 | 91 | 287 |
| Not Hispanic or Latino | 156 | 153 | 159 | 468 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 22 | 24 | 23 | 69 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 23 | 21 | 22 | 66 |
| White | 201 | 204 | 203 | 608 |
| More than one race | 3 | 5 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| United States | 132 | 137 | 139 | 408 |
| Czech Republic | 12 | 12 | 13 | 37 |
| Puerto Rico | 12 | 14 | 14 | 40 |
| Canada | 34 | 32 | 30 | 96 |
| Argentina | 29 | 28 | 25 | 82 |
| Brazil | 8 | 6 | 7 | 21 |
| Denmark | 9 | 11 | 8 | 28 |
| India | 15 | 14 | 14 | 43 |
| Body Mass Index (BMI)(kilograms/square meters (kg/m^2)) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.80 ± 5.66 | 32.55 ± 5.86 | 33.53 ± 6.49 | 32.96 ± 6.02 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.93 ± 0.76 | 7.91 ± 0.73 | 7.94 ± 0.78 | 7.93 ± 0.76 |
| Body Weight(kilogram (kg)) | 1.5 Milligram (mg) LY2189265 | 0.75 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|
| Mean | 90.42 ± 18.58 | 90.45 ± 18.74 | 93.90 ± 21.26 | 91.58 ± 19.60 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2010, a primary completion of Sep 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 3 years 5 months after primary completion. A results delay was requested in Nov 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide